2/11
08:04 am
nvct
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights [Yahoo! Finance]
2/11
07:30 am
nvct
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Low
Report
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
12/17
07:16 am
nvct
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]
Low
Report
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]
12/17
07:00 am
nvct
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Low
Report
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
12/3
08:44 am
nvct
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
09:08 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
Low
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
11/25
08:00 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Medium
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC